Abstract
Recent advances in the field of nanotechnology have given a boost to the academic researchers, the pharmaceutical and biomedical industry, allowing its use in drug delivery and medical diagnosis. Nanotechnology allows the formulation of drug delivery carriers in the nanometer range that helps in overcoming disadvantages associated with conventional drug delivery systems by being small, target-specific, improved drug encapsulation, stable and less toxic at the same time. With nanotechnology, many drugs especially oncogenic molecules that are toxic or are difficult to deliver have been formulated and delivered successfully and are currently in the market, for example, Myocet® (2000) (Doxorubicin) and Marqibo® (2012) (Vincristine). Nanoparticle-based drug delivery carriers can be classified into two types; organic and inorganic. Organic nanoparticles are mostly used for drug delivery, while inorganic nanoparticles are majorly involved in diagnosis. Organic nanoparticles generally involve but are not limited to liposomes, dendrimers, polymeric micelles, polymeric nanoparticles, and solid lipid nanoparticles. Inorganic nanoparticles involve metals such as gold, silver, and iron oxide. In this chapter, we will discuss the advantages and disadvantages of nanoparticles and various materials that are used for making different types of nanoparticles with relevant examples. Further, we will discuss the recent developments in this field with some examples pertaining to each type of nanoparticles.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Geszke-Moritz M, Moritz M. Quantum dots as versatile probes in medical sciences: synthesis, modification and properties. Mater Sci Eng C. 2013;33(3):1008–21. https://doi.org/10.1016/j.msec.2013.01.003.
Mehra NK, Jain K, Jain NK. Pharmaceutical and biomedical applications of surface engineered carbon nanotubes. Drug Discov Today. 2015;20(6):750–9. https://doi.org/10.1016/j.drudis.2015.01.006.
Nanda SS, Papaefthymiou GC, Yi DK. Functionalization of graphene oxide and its biomedical applications. Crit Rev Solid State Mater Sci. 2015;40(5):291–315. https://doi.org/10.1080/10408436.2014.1002604.
Moritz M, Geszke-Moritz M. Recent Developments in application of polymeric nanoparticles as drug carriers. Adv Clin Exp Med. 2015;24(5):749–58. https://doi.org/10.17219/acem/31802.
Moritz M, Geszke-Moritz M. The newest achievements in synthesis, immobilization and practical applications of antibacterial nanoparticles. Chem Eng J. 2013;228:596–613. https://doi.org/10.1016/j.cej.2013.05.046.
Labieniec-Watala M, Watala C. PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications. J Pharm Sci. 2015;104(1):2–14. https://doi.org/10.1002/jps.24222.
Moritz M, Geszke-Moritz M. Mesoporous materials as multifunctional tools in biosciences: principles and applications. Mater Sci Eng C. 2015;49:114–51. https://doi.org/10.1016/j.msec.2014.12.079.
Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C. 2016;68:982–94. https://doi.org/10.1016/j.msec.2016.05.119.
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR, Corrie SR. Nanoparticle-based medicines : a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–87. https://doi.org/10.1007/s11095-016-1958-5.
Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;(February):10–29. doi:https://doi.org/10.1002/btm2.10003
Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine. 2014:4357–73.
Ling L, Ismail M, Du Y, et al. High drug loading, reversible Disulfide Core-cross-linked multifunctional micelles for triggered release of Camptothecin. Mol Pharm. 2018;15:5479–92. https://doi.org/10.1021/acs.molpharmaceut.8b00585.
Liu Z, Chen M, Guo Y, et al. Self-assembly of cationic amphiphilic cellulose-g-poly (p-dioxanone) copolymers. Carbohydr Polym. 2019;204(October 2018):214–22. https://doi.org/10.1016/j.carbpol.2018.10.020.
Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech. 2014;15(4):862–71. https://doi.org/10.1208/s12249-014-0113-z.
Deng C, Jiang Y, Cheng R, Meng F, Zhong Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today. 2012;7(5):467–80. https://doi.org/10.1016/j.nantod.2012.08.005.
Deshmukh AS, Chauhan PN, Noolvi MN, et al. Polymeric micelles: basic research to clinical practice. Int J Pharm. 2017;532(1):249–68. https://doi.org/10.1016/j.ijpharm.2017.09.005.
Jin X, Yang Q, Cai N. Preparation of ginsenoside compound-k mixed micelles with improved retention and antitumor efficacy. Int J Nanomedicine. 2018;13:3827–38. https://doi.org/10.2147/IJN.S167529.
Wang L-L, He D-D, Wang S-X, Dai Y-H, Ju J-M, Zhao C-L. Preparation and evaluation of curcumin-loaded self-assembled micelles. Drug Dev Ind Pharm. 2018;44(4):563–9. https://doi.org/10.1080/03639045.2017.1405431.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–60.
Li Y, Xiao K, Zhu W, Deng W, Lam KS. Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers. Adv Drug Deliv Rev. 2014;66:58–73. https://doi.org/10.1016/j.addr.2013.09.008.
Wang H, Tang L, Tu C, et al. Redox-responsive, core-cross-linked micelles capable of on-demand, concurrent drug release and structure disassembly. Biomacromolecules. 2013;14(10):3706–12. https://doi.org/10.1021/bm401086d.
Lee CC, MacKay JA, Fréchet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23:1517–26.
Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2012;64:102–15. https://doi.org/10.1016/j.addr.2012.09.030.
Liu M, Fréchet JMJ. Designing dendrimers for drug delivery. Pharm Sci Technolo Today. 1999;2(10):393–401. https://doi.org/10.1016/S1461-5347(99)00203-5.
Mendes LP, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1–21. https://doi.org/10.3390/molecules22091401.
Hammer BAG, Müllen K. Expanding the limits of synthetic macromolecular chemistry through Polyphenylene Dendrimers. J Nanoparticle Res. 2018;20(10) https://doi.org/10.1007/s11051-018-4364-6.
Kageyama A, Yanase M, Yuguchi Y. Structural characterization of enzymatically synthesized glucan dendrimers. Carbohydr Polym. 2019;204(September 2018):104–10. https://doi.org/10.1016/j.carbpol.2018.09.053.
Kotrchová L, Kostka L, Etrych T. Drug carriers with star polymer structures. Physiol Res. 2018;67(Suppl. 2):S293–303.
Jędrzak A, Grześkowiak BF, Coy E, et al. Dendrimer based theranostic nanostructures for combined chemo- and photothermal therapy of liver cancer cells in vitro. Colloids Surfaces B Biointerfaces. 2019;173(June 2018):698–708. https://doi.org/10.1016/j.colsurfb.2018.10.045.
Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001;6(8):427–36. https://doi.org/10.1016/S1359-6446(01)01757-3.
Chang H, Wang H, Shao N, Wang M, Wang X, Cheng Y. Surface-engineered dendrimers with a Diaminododecane core achieve efficient gene transfection and low cytotoxicity. Bioconjug Chem. 2014;25(2):342–50. https://doi.org/10.1021/bc400496u.
Watkins DM, Sayed-Sweet Y, Klimash JW, Turro NJ, Tomalia DA. Dendrimers with hydrophobic cores and the formation of supramolecular dendrimer−surfactant assemblies. Langmuir. 1997;13(12):3136–41. https://doi.org/10.1021/la9620263.
Liu C, Gao H, Zhao Z, et al. Improved tumor targeting and penetrating by dual-functional poly(amidoamine) dendrimer for the therapy of triple-negative breast cancer. J Mater Chem B. 2019;7:3724–36. https://doi.org/10.1039/C9TB00433E.
Wang K, Hu Q, Zhu W, Zhao M, Ping Y, Tang G. Structure-invertible nanoparticles for triggered co-delivery of nucleic acids and hydrophobic drugs for combination cancer therapy. Adv Funct Mater. 2015;25(22):3380–92. https://doi.org/10.1002/adfm.201403921.
Li Y, Wang H, Wang K, et al. Targeted co-delivery of PTX and TR3 siRNA by PTP peptide modified dendrimer for the treatment of pancreatic cancer. Small. 2017;13(2):1602697. https://doi.org/10.1002/smll.201602697.
Gu Y, Guo Y, Wang C, et al. A polyamidoamne dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery. Mater Sci Eng C. 2017;70:572–85. https://doi.org/10.1016/j.msec.2016.09.035.
Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, Torchilin VP. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013;34(4):1289–301. https://doi.org/10.1016/j.biomaterials.2012.10.024.
Han M, Lv Q, Tang X-J, et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release. 2012;163(2):136–44. https://doi.org/10.1016/j.jconrel.2012.08.020.
Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193 LP–6204. https://doi.org/10.1158/1078-0432.CCR-13-1536.
Patil YP, Jadhav S. Novel methods for liposome preparation. Chem Phys Lipids. 2014;177:8–18. https://doi.org/10.1016/j.chemphyslip.2013.10.011.
Carugo D, Bottaro E, Owen J, Stride E, Nastruzzi C. Liposome production by microfluidics: potential and limiting factors. Sci Rep. 2016;6:1–15. https://doi.org/10.1038/srep25876.
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60. https://doi.org/10.1038/nrd1632.
Peng S, Zou L, Liu W, et al. Hybrid liposomes composed of amphiphilic chitosan and phospholipid: preparation, stability and bioavailability as a carrier for curcumin. Carbohydr Polym. 2017;156:322–32. https://doi.org/10.1016/j.carbpol.2016.09.060.
Rahman M, Beg S, Anwar F, et al. Liposome-based nanomedicine therapeutics for rheumatoid arthritis. Crit Rev Ther Drug Carrier Syst. 2017;34(4):283–316. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2017016067.
Nunes SS, Luis A, De Barros B. Journla of molecular pharmaceutics & organic process research the use of coating agents to enhance liposomes blood circulation time. J Mol Pharm Org Process Res. 2015;3(1):1–2. https://doi.org/10.4172/2329-9053.1000e120.
Yang T, Cui F, Choi M, Cho J. Enhanced solubility and stability of PEGylated liposomal paclitaxel : In vitro and in vivo evaluation. Int J Pharm. 2007;338:317–26. https://doi.org/10.1016/j.ijpharm.2007.02.011.
Monpara J, Kanthou C, Tozer GM, Vavia PR. Rational design of cholesterol derivative for improved stability of paclitaxel cationic liposomes. Pharm Res. 2018:1–17.
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):1–33. https://doi.org/10.3390/pharmaceutics9020012.
Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–72. https://doi.org/10.1016/j.addr.2003.12.002.
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–58. https://doi.org/10.4103/0250-474X.57282.
Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7–22. https://doi.org/10.1016/j.ejpb.2013.08.013.
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(SUPPL.):131–155. doi:https://doi.org/10.1016/S0169-409X(02)00118-7
Rostami E, Kashanian S, Azandaryani AH. Preparation of solid lipid nanoparticles as drug carriers for levothyroxine sodium with in vitro drug delivery kinetic characterization. Mol Biol Rep. 2014;41(5):3521–7. https://doi.org/10.1007/s11033-014-3216-4.
Soares S, Fonte P, Costa A, et al. Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles. Int J Pharm. 2013;456(2):370–81. https://doi.org/10.1016/j.ijpharm.2013.08.076.
Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2011;63(3):342–51. https://doi.org/10.1111/j.2042-7158.2010.01225.x.
Shi S, Han L, Deng L, et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014;194:228–37. https://doi.org/10.1016/j.jconrel.2014.09.005.
Ying X-Y, Cui D, Yu L, Du Y-Z. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polym. 2011;84(4):1357–64. https://doi.org/10.1016/j.carbpol.2011.01.037.
Kuo Y-C, Chung J-F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surfaces B Biointerfaces. 2011;83(2):299–306. https://doi.org/10.1016/j.colsurfb.2010.11.037.
Kuo Y-C, Liang C-T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials. 2011;32(12):3340–50. https://doi.org/10.1016/j.biomaterials.2011.01.048.
Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine Nanotechnology, Biol Med. 2013;9(1):111–21. https://doi.org/10.1016/j.nano.2012.03.003.
Eid HM, Elkomy MH, El Menshawe SF, Salem HF. Development, optimization, and In Vitro/In Vivo characterization of enhanced lipid nanoparticles for ocular delivery of Ofloxacin: the influence of pegylation and chitosan coating. AAPS PharmSciTech. 2019;20(183):1–14. https://doi.org/10.1208/s12249-019-1371-6.
Jain P, Pandey V, Soni V. Surface modified solid lipid nanoparticles for brain cancer treatment. Asian J Pharm. 2019;13(2):119–24.
Arana L, Bay L, Sarasola LI, Berasategi M, Ruiz S, Alkorta I. Solid lipid nanoparticles surface modification modulates cell internalization and improves Chemotoxic treatment in an Oral carcinoma cell line. Nano. 2019;9(3):1–17. https://doi.org/10.3390/nano9030464.
Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887–913. https://doi.org/10.1016/j.progpolymsci.2011.01.001.
El-Say KM, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017;528(1–2):675–91. https://doi.org/10.1016/j.ijpharm.2017.06.052.
Vauthier CCP. Development of nanoparticles made of polysaccharides as novel drug carrier systems. Handb Pharm Control Release Technol. 2000:13–429.
Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles : current possibilities and future trends. Eur J Pharm Biopharm. 1995;41(1):2–13.
Jeanmonod DJ, Rebecca, Suzuki K, et al. We are IntechOpen, the world ’ s leading publisher of Open Access books Built by scientists, for scientists TOP 1% Control of a Proportional Hydraulic System. Intech open. 2018;2(64) https://doi.org/10.5772/32009.
Ahmed TA, El-Say KM. Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole. Life Sci. 2014;110(1):35–43. https://doi.org/10.1016/j.lfs.2014.06.019.
Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, José AM. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16(10):1576–81. https://doi.org/10.1023/A:1018908705446.
Kaul G, Amiji M. Biodistribution and targeting potential of poly(ethylene glycol)-modified Gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target. 2004;12(9–10):585–91. https://doi.org/10.1080/10611860400013451.
Luppi B, Bigucci F, Corace G, et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci. 2011;44(4):559–65. https://doi.org/10.1016/j.ejps.2011.10.002.
Edlund U, Albertsson A-C. Degradable polymer microspheres for controlled drug delivery BT – degradable aliphatic polyesters. In: Berlin, Heidelberg: Springer Berlin Heidelberg; 2002:67–112. doi:https://doi.org/10.1007/3-540-45734-8_3
Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325(1):172–9. https://doi.org/10.1016/j.ijpharm.2006.06.023.
Zambaux MF, Bonneaux F, Gref R, et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release. 1998;50(1):31–40. https://doi.org/10.1016/S0168-3659(97)00106-5.
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–22. https://doi.org/10.1016/j.jconrel.2012.01.043.
Grabrucker AM, Garner CC, Boeckers TM, et al. Development of novel Zn2+ loaded Nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. PLoS One. 2011;6(3) https://doi.org/10.1371/journal.pone.0017851.
Nagavarma BVN, Yadav HKS, Ayaz A, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles- A review. Asian J Pharm Clin Res. 2012:16–23. doi:ISSN-0974-2441.
Saroja C, Lakshmi P, Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig. 2011;1(2):64–74. https://doi.org/10.4103/2230973X.82384.
Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: characterization, degradation, and release characteristics. J Biomed Mater Res. 1985;19(8):941–55. https://doi.org/10.1002/jbm.820190806.
González-Martı́n G, Figueroa C, Merino I, Osuna A. Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur J Pharm Biopharm 2000;49(2):137–142. doi:https://doi.org/10.1016/S0939-6411(99)00076-4.
Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Reports. 2012;64(5):1020–37. https://doi.org/10.1016/S1734-1140(12)70901-5.
Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971–3010. https://doi.org/10.1039/C2CS15344K.
Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine Nanotechnology, Biol Med. 2006;2(1):8–21. https://doi.org/10.1016/j.nano.2005.12.003.
Thickett SC, Gilbert RG. Emulsion polymerization: state of the art in kinetics and mechanisms. Polymer (Guildf). 2007;48(24):6965–91. https://doi.org/10.1016/j.polymer.2007.09.031.
Bhavsar MD, Amiji MM. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv. 2007;4(3):197–213. https://doi.org/10.1517/17425247.4.3.197.
Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. Design of Biodegradable Nanoparticles for Oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;26(3):492–501. https://doi.org/10.1007/s11095-008-9763-4.
Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649–59. https://doi.org/10.1016/j.addr.2004.02.014.
Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified Gelatin nanoparticles for intracellular delivery. Pharm Res. 2002;19(7):1061–7. https://doi.org/10.1023/A:1016486910719.
Shah M, Naseer MI, Choi MH, Kim MO, Yoon SC. Amphiphilic PHA–mPEG copolymeric nanocontainers for drug delivery: preparation, characterization and in vitro evaluation. Int J Pharm. 2010;400(1):165–75. https://doi.org/10.1016/j.ijpharm.2010.08.008.
Asua JM. Emulsion polymerization: from fundamental mechanisms to process developments. J Polym Sci Part A Polym Chem. 2004;42(5):1025–41. https://doi.org/10.1002/pola.11096.
Wang J-W, Kuo Y-M. Preparation and adsorption properties of chitosan–poly(acrylic acid) nanoparticles for the removal of nickel ions. J Appl Polym Sci. 2008;107(4):2333–42. https://doi.org/10.1002/app.27247.
Lohmeyer JHGM, Tan YY, Challa G. Polymerization of Methacrylic acid in the presence of isotactic poly(methyl methacrylate) as possible template. J Macromol Sci Part A – Chem. 1980;14(6):945–57. https://doi.org/10.1080/00222338008068122.
Al-Nemrawi KN, Alshraiedeh HN, Zayed LA, Altaani MB. Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharm. 2018;11(1) https://doi.org/10.3390/ph11010028.
Deacon J, Abdelghany SM, Quinn DJ, et al. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). J Control Release. 2015;198:55–61. https://doi.org/10.1016/j.jconrel.2014.11.022.
Muttil P, Prego C, Garcia-Contreras L, et al. Immunization of Guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010;12(3):330–7. https://doi.org/10.1208/s12248-010-9192-2.
Muttil P, Pulliam B, Garcia-Contreras L, et al. Pulmonary immunization of Guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 2010;12(4):699–707. https://doi.org/10.1208/s12248-010-9229-6.
Khademi F, Yousefi-Avarvand A, Derakhshan M, Abbaspour MR, Sadri K, Tafaghodi M. Formulation and optimization of a new cationic lipid-modified PLGA nanoparticle as delivery system for Mycobacterium tuberculosis HspX/EsxS fusion protein: an experimental design. Iran J Pharm Res IJPR. 2019;18(1):446–58.
Kunda NK, Alfagih IM, Dennison SR, et al. Bovine serum albumin adsorbed PGA-CO-PDL nanocarriers for vaccine delivery via dry powder inhalation. Pharm Res. 2015;32(4):1341–53. https://doi.org/10.1007/s11095-014-1538-5.
Mohamed A, Kunda NK, Ross K, Hutcheon GA, Saleem IY. Polymeric nanoparticles for the delivery of miRNA to treat chronic obstructive pulmonary disease (COPD). Eur J Pharm Biopharm. 2019;136(July 2018):1–8. https://doi.org/10.1016/j.ejpb.2019.01.002.
Alaqad K, Saleh T. Gold and silver nanoparticles: synthesis methods, characterization routes and applications towards drugs. J Environ Anal Toxicol. 2016;6(4):1–10. https://doi.org/10.4172/2161-0525.1000384.
Etame AB, Smith CA, Chan WCW, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine Nanotechnology, Biol Med. 2011;7(6):992–1000. https://doi.org/10.1016/j.nano.2011.04.004.
Tedesco S, Doyle H, Blasco J, Redmond G, Sheehan D. Oxidative stress and toxicity of gold nanoparticles in Mytilus edulis. Aquat Toxicol. 2010;100(2):178–86. https://doi.org/10.1016/j.aquatox.2010.03.001.
Carabineiro AS. Applications of gold nanoparticles in nanomedicine: recent advances in vaccines. Mol. 2017;22(5) https://doi.org/10.3390/molecules22050857.
Versiani AF, Andrade LM, Martins EMN, et al. Gold nanoparticles and their applications in biomedicine. Future Virol. 2016;11(4):293–309. https://doi.org/10.2217/fvl-2015-0010.
Jain S, Hirst DG, O’Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(1010):101–13. https://doi.org/10.1259/bjr/59448833.
Mandal NPP and TK. Engineered Nanoparticles in Cancer Therapy. Recent Pat Drug Deliv Formul. 2007;1(1):37–51. doi:https://doi.org/10.2174/187221107779814104
Qian Y, Qiu M, Wu Q, et al. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Sci Rep. 2014;4:7490. https://doi.org/10.1038/srep07490.
Ramalingam V, Varunkumar K, Ravikumar V, Rajaram R. Target delivery of doxorubicin tethered with PVP stabilized gold nanoparticles for effective treatment of lung cancer. Sci Rep. 2018;8(1):3815. https://doi.org/10.1038/s41598-018-22172-5.
Niikura K, Matsunaga T, Suzuki T, et al. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano. 2013;7(5):3926–38. https://doi.org/10.1021/nn3057005.
De Matteis V, Cascione M, Toma CC, Leporatti S. Silver nanoparticles: synthetic routes, In Vitro toxicity and theranostic applications for cancer disease. Nanomater (Basel, Switzerland). 2018;8(5):319. https://doi.org/10.3390/nano8050319.
Li W-R, Xie X-B, Shi Q-S, Zeng H-Y, OU-Yang Y-S, Chen Y-B. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol. 2010;85(4):1115–22. https://doi.org/10.1007/s00253-009-2159-5.
Zhang X-F, Liu Z-G, Shen W, Gurunathan S. Silver nanoparticles: synthesis, characterization, properties, applications, and therapeutic approaches. Int J Mol Sci. 2016;17(9):1534. https://doi.org/10.3390/ijms17091534.
Carlson C, Hussain SM, Schrand AM, et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B. 2008;112(43):13608–19. https://doi.org/10.1021/jp712087m.
Gurunathan S, Park JH, Han JW, Kim J-H. Comparative assessment of the apoptotic potential of silver nanoparticles synthesized by Bacillus tequilensis and Calocybe indica in MDA-MB-231 human breast cancer cells: targeting p53 for anticancer therapy. Int J Nanomedicine. 2015;10:4203–22. https://doi.org/10.2147/IJN.S83953.
He Y, Du Z, Ma S, et al. Effects of green-synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo. Int J Nanomedicine. 2016;11:1879–87. https://doi.org/10.2147/IJN.S103695.
Yang XX, Li CM, Huang CZ. Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. Nanoscale. 2016;8(5):3040–8. https://doi.org/10.1039/C5NR07918G.
Shedbalkar U, Singh R, Wadhwani S, Gaidhani S, Chopade BA. Microbial synthesis of gold nanoparticles: current status and future prospects. Adv Colloid Interf Sci. 2014;209:40–8. https://doi.org/10.1016/j.cis.2013.12.011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Chavan, T., Muttil, P., Kunda, N.K. (2020). Introduction to Nanomedicine in Drug Delivery. In: Muttil, P., Kunda, N. (eds) Mucosal Delivery of Drugs and Biologics in Nanoparticles. AAPS Advances in the Pharmaceutical Sciences Series, vol 41. Springer, Cham. https://doi.org/10.1007/978-3-030-35910-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-35910-2_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35909-6
Online ISBN: 978-3-030-35910-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)